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• 
Chronic progressive extern al ophthalmoplegia (CPEO) is caused by a decreased oxidative 
phosphorylation (OXPHOS) activity due to large-scale deletions of the mitochondrial 
genome in 50 % of the patients. The deletions encompass structural OXPHOS genes as 
weil as tRNA genes, required for their expression so that the pathogenesis could be due to 
the deleted OXPHOS subunits or to an impaired mitochondrial translation. We have 
analyzed the mitochondrial genome of a patient presenting with CPEO for single base 
substitutions and discovered a novel heteroplasmic mutation in the tRNAA,n gene at 
position 5692 that converts a highly conserved adenine into a guanine. This mutation is 
unique because it is located at the transition of the anticodon loop to the anticodon stern 
and it leads to an additional base pair, thus reducing the number of loop-forming 
nucleotides from seven to five. Our findings suggest that CPEO can be caused by a single 
base substition in a mitochondrial tRNA gene so that the mitochondrial protein synthesis 
becomes the rate limiting step in OXPHOS fidelity. <, 1994 Aeademc Press, Ine. 
Chronic progressive extemal ophthalmoplegia (CPEO) and Keams-Sayre syndrome (KSS) have 
been shown to fulfill the criteria for mitochondrial DNA (mtDNA) mutation. The disease is 
either sporadic (I) or matemally inherited (2), aIthough autosomal inheritance has been reported 
(3). It is associated with severe defects of the oxidative phosphorylation (OXPHOS) complexes 
I, II1, IV and V (4-6), subunits of which are encoded by the mitochondrial DNA (7). The severity 
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of patient' s symptoms varies, consistent with a mitotic or meiotic segregation of a heteroplasmic 
mutated mtDNA. FinaHy, as the patient's mitochondrial ATP-generating capacity declines, 
tissues of the central nervous system, skeletal muscle and heart are progressively affected, 
indicating that tissue-specific energetic thresholds are being traversed by the shift of 
heteroplasmy towards mutated mitochondrial DNA (8). Genetically, the OXPHOS system is 
expressed under the combined control of the nuclear and the mitochondrial genome (7) that 
codes for seven subunits of complex I (NADH-ubiquinol oxidoreductase), one subunit of 
complex III (ubiquinol-cytochrome c oxidoreductase), three subunits ofcomplex IV (cytochrome 
c oxidase) and two subunits of complex V (ATP synthase). Additionally, it harbors the 12 Sand 
16 S rRNA genes, as weH as a set of 22 tRNAs, required for the expression of the OXPHOS 
genes. Detailed RFLP-analyses of patients with CPEO revealed heteroplasmic length variations 
of the mitochondrial genome (1,9,10). The most frequent "common deletion" spans 4977 bps, 
covering genes for complex I, IV and V as weH as tRNA genes for glycine, arginine, histidine, 
serine and leueine (1,11). Thus, the pathogenicity of mtDNA deletions causing CPEO could be 
due to three different processes: first, the deletion encompasses structural OXPHOS genes, so 
that depending on the degree of heteroplasmy within single mitochondria, deleted OXPHOS 
subunits cannot be synthesized (homoplasmic deleted genomes) or will be synthesized not in the 
required stoichiometries. Second, deletions generate fusion genes, so that expressed chimeric 
OXPHOS proteins could interfere with the assembly and functioning of the complexes. Third, 
besides the structural OXPHOS genes, the deletions always comprise essential tRNA genes. As a 
result of deleted genomes within single mitochondria, a decreased protein synthesis rate could 
cause the described OXPHOS deficiencies in patients with CPEO. Compatible with the latter 
described pathogenicity of mtDNA deletions is the recent observation that the mitochondrial 
tRNA Leu mutation at nucleotide pair 3243, previously attributed to cause mitochondrial 
encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS), can be associated with 
progressive external ophthalmoplegia (PEO) (12). In fact, it has been demonstrated that 
mutations in tRNA genes lead to an impaired mitochondrial protein synthesis in cultured cells of 
patients with myoclonic epilepsy and ragged-red fibers disease (MERRF) (13) and MELAS (14). 
This led us to the hypothesis that CPEO could be caused by yet unknown deleterious base 
substitution in mitochondrial genes essential for functional translation, mimicring adepleted 
• 
tRNA caused by a mtDNA deletion. Data presented in this paper support this speculation. By 
sequencing the mitochondrial genome of a patient presenting clinicaHy with CPEO (without 
length variation), we identified a novel heteroplasmic single base replacement that changes an A 
to a G in the anticodon loop of the tRN A Asn. This mutation, located near to the origin of light 
strand replication, converts a highly conserved nucleotide at position 5692 and was neither found 
in six unrelated caucasian controls nor in any other population studied so far (15-17). Thus, the 
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mutation eould aeeount for the pleiotropic phenotypie and biochemieal eharaeteristics associated 
with the disease. 
MATERIALS AND METHODS 
Patient. The patient had ophthalmoplegia, muscle weakness of the lower limbs, a severe 
neuropathy, eerebellar signs and beginning eardiac dysfunction. Biochemieally, there was a 
:Slight reduetion of complexes I and IV of the respiratory chain. Histochemically, a few 
ragged-red fibers appeared on Gomori tri chrome staining. 
Isolation of genomic DNA. Total DNA was prepared from about 100 mg of frozen muscle 
biopsy speeimens by the method of Seibel et al. (13). 
Southern hlot analysis. Two mierograms of total DNA were digested with Pvu 11 or Bam Hf, 
eleetrophoresed on a 0.5 % agarose gel and transferred onto nylon membranes (18). The filters 
were hybridized to a random primer-extended probe generated from mtDNA isolated from 
human placenta. 
Polymerase ehain reaetion. PCR was used to generate mitoehondrial DNA fragments for 
sequeneing and for the detection of mutated and wild-type mtDNA by RFLP analysis (19). 
Asymmetrieally PCR-amplified DNA for dideoxynucleotide ehain-tenninating sequeneing was 
prepared by adding one primer in 100-fold excess of the other (molar ratio: 30 pmol : 0.3 pmol). 
Primers used for amplijieation and sequencing. Forward primers annealed to nucleotides (nt) 
534-553, 1562-1581, 3007-3023, 3951-3970, 5317-5333, 7392-7410, 8150-8166, 9911- 9932, 
11979-11995, 14407-14424, 15553-15569, whereas reverse primers were loeated at nucleotides 
725-706,1696-1677,3717-3701,4508-4489, 6263-6247, 7608-7588,8628-8608,10728-10712, 
12576-12557,15153-15135, 16159-16142 ofthe published sequence (7). 
DNA sequencing. Sequeneing primers were annealed to single-stranded DNA generated by 
asymmetrie PCR and segenced as described by Shoffner et al. (8). 
RFLP analysis. 500 ng of PCR-generated DNA amplified with the forward primer annealing to 
nt 4828-4848 and areverse primer located at nt 6266-6246 was purified by precipitation and 
digested with the restriction endonuclease Hpa f (10 units) for 3 h. The DNA fragments were 
resolved on a 1.2 % agarose gel and visualized by ethidium bromide staining under UV light. 
Quantijication of heteroplasmie mtDNA. Heteroplasmic mtDNA was quantifieated by the 
modified method of Sei bel et al. (20). After 25 cycles, peR was interrupted, supplemented with 
32P-Iabeled dATP and restarted for an extra cycle, followed by Hpa J-RFLP analysis. 
DNA-fragments were exeised from an agarose gel and quantificated by counting the 32p radiation 
using a liquid seintillation counter. 
RESULTS 
Southern blot analysis of patient' s genomie DNA revealed no major length alteration (> 1.5 kb) 
of the mitochondrial genome, as the mtDNA formed only a single band of 16.5 kb in size. 
Further restriction endonuclease mapping of the genomic DNA excluded also small mtDNA 
deletions (> 0.3 kb, data not shown). To study if any gene of the mitochondrial encoded 
translation apparatus was altered, the mitoehondrial genome of the patient was amplified in 11 
fragments (eneompassing all tRNA and rRNA genes) and sequenced. A mutation was found at 
position 5692 (see fig. 1 a, left panel), almost 40 nucleotides upstream of the origin of light 
strand mtDNA replication. The mutation appeared heteroplasmically upon sequenee analysis. To 
determine if this mutation contributes to the pathogenieity of the disease, the same region was 
sequenced from a eontrol subject, whose DNA sequence revealed exclusively the wild-type 
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adenine at this loeation (see fig. la, right panel). This analysis was extended to additional 
patients and eontrols by utilizing the restrietion endonuclease Hpa I. This enzyme cleaves the 
wild-type sequenee (GTT AAC), while the mutated sequenee (GTT AGC) is not aItered. Hpa 1-
RFLP analysis of PCR-generated DNA fragments resulted in fragments of 863 bp and 575 bp in 
ease of wild-type mtDNA, hut in an unaltered fragment of 1438 bp in the ease of the mutation. 
The patient's DNA was analyzed together with six unrelated eaueasian eontrols. While the 
patient's analysis revealed mutated and wild-type mtDNA (heteroplasmy), as expeeted from the 
sequenee analysis, the mutation was not found in the eontrols (see fig. 1 b). Furthermore, the test 
failed to deteet the mutation in twelve unrelated CPEO patients without deletions. Using this test 
in a quantitative manner, the mitoehondrial genotype of the patient was estimated with 
about 56 % mutated and 44 % wild-type mtDNA. 
To assess the funetional signifieanee of nucleotide pair 5692, we aligned the human tRNA Asn 
with the sequenees from other speeies (see fig. 2a) relative to eonserved stem regions (21). In 
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Figure 1. Sequence and Hpa I-RFLP analysis ofthe mutated and the wild-type mttRNAA'"-gene. 
a: The arrows indicate nucleotide 5692 of the human mitochondrial genome (7). Left panel: 
wild-type sequence of a control subject; right panel: heteroplasmic mutated mtDNA of a patient 
presenting with CPEO. b: Mutated mtDNA results in an unaltered fragment of 1438 bp, 
whereas the wild-type mtDNA is cleaved into two fragments of 863 bp and 575 bp. Lane 1: 
molecular weight marker X (Boehringer Mannheim); lane 2: patient with CPEO; lanes 3-8: 
caucasian controls; lane 9: molecular weight marker ~X 174 RF DNA digested with Hae III 
(New England Biolabs). 
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this alignment, the A was present in all other species from rat to sea urchin. Hence, nucleotide 
5692 of the anticodon loop appears to be functionally conserved and its substitution could affect 
tRNAAsn function. 
To iIlustrate how the function of the mutated tRNA could be affected, we studied the structural 
changes taking place in the anticodon loop of the mutated tRNA Asn. As was predicted by 
computer analysis (22), the wild-type mttRNA Asn fonns a c1over-leaf structure with an anticodon 
loop of seven unmatched nuc1eotides. whereas its anticodon stern is formed by five base pairs 
(see fig. 2b). The energy released during fonnation of stern and loop was estimated under 
standardized conditions [1 M Na-; pH = 7.0; T = 298.15 K] with -11.1 kllmol (23,24). The same 
analysis carried out for the mutated tRNA Asn led to a reorganization of the anticodon loop, as the 
mutated nucleotide fOlms now an additional hybrid pair with its counterpart. Therefore, the 
number of loop-forming nuc1eotides is decreased by two so that only five bases remain, whereas 
the stern is extended by an extra base pair. This results in an energy release of totally -30.5 
kllmo!. As a consequence of the extra base pair formation, a further hybrid could be fOlll1ed by 
the next couple of bases (see fig. 2b), leading to an extra extension of the stern by one base pair 
(total length: seven base pairs) so that only three bases remain to fOlm the anticodon loop. The 
energy release for this formation is estimated with -23.0 kllmo!. 
DISCUSSION 
The association of CPEO and KSS with large scale deletions of the mitochondrial genome has 
been reported before (1,9,10). However, this accounts only for 50 % of the cases, the molecular 
basis of the others remains unclear, although an association of the MELAS mutation at 
nucleotide pair 3243 has been reported for patients with PEO (12). The c1assical CPEO genotype 
(mtDNA deletion) results in a reduced OXPHOS activity. The pathogenic mechanism leading to 
the reduction is poorly understood and has been discussed controversely in the literature (25,26). 
Most likely, the reduction of respiratory chain activity is due to the impaired mitochondrial 
translation rate caused by the deleted tRNA genes. If so, a mutation in a mitochondrial gene of 
the protein synthesis apparatus could result in a similar OXPHOS deficiency. Thus, we searched 
for a mutation in the mitochondrial genome of a patient with CPEO presenting no length 
variation that could explain similar pleiotropic phenotypic and biochemical alterations 
(biochemically: slightly reduced activity of complex I and IV, histochemically: ragged-red 
fibers). Only a single heteroplasmic nucleotide conversion was detected in this patient, which 
met all the criteria expected for a mutation causing CPEO: first, it is the only mutation in the 
sequenced tRNA and rRNA genes that alters a highly conserved element (see fig. 2a). Second, it 
correlates perfectly with the disease: it was only found in the patient's genome and has not been 
found in our caucasian controls. Our data are corroborated by population genetic studies: Hpa 1 
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is widely used in RFLP analysis and so far, a variation at mtDNA position 5692 has never been 
observed in any other population (15-17). Third, it alters the tRNA in a way that could explain 
the decreased OXPHOS activity by a diminished mitochondrial protein synthesis rate. Fourth, it 
is heteroplasmic, consistent with arecent origin for a mutation. The shift from wild-type to 
almost complete mutated mtDNA takes place by the slow mechanism of mitotic or meiotic 
segregation (27). The time required to enforce the mutation to homoplasmy is about four 
generations (Seibel, unpublished data, estimated from the tRNALeu mutation at nucleotide pair 
3243, previously attributed to MELAS). Thus, the tRNA Asn mutation at position 5692 fuHiIIs all 
the criteria predicted for a deleterious mutation and hence is most likely associated with the 
disease. Furthellnore, our findings support the hypothesis that diverse, yet unknown mutations in 
genes functioning in mitochondrial protein synthesis could contribute to the pathogenicity of 
CPEO in other cases as weIl. 
The mechanism, how the mutation leads to a decreased respiratory chain activity as a result of an 
impaired translation, is unclear. Most likely, the secondary structure of the mitochondrial 
tRNAAsn is altered so that the tertiary structure of the anti co don loop is displaced. Following 
thermodynamic rules, systems always try to reach the lowest level of energy. Thus, the predicted 
tRNA Asn structure containing five anticodon loop-forming nucleotides is favoured during the 
formation process of the tRNA. The energy released during this process (dOo = -30.4 kJ/mol) is 
almost identical to the amount of energy released during the hydrolysis of ATP to ADP and 
phosphate (dOo = -30.5 kJ/mo!), indicating the stability ofthe formed loop-stem-structure. Thus, 
inhibition of assembly of the ribosome-mRNA-tRNA-complex required for a functional 
translation could be easily explained by the novel tertiary structure of the mutated tRNAA,n. 
Other pathogenic mechanisms, however, as for instance an incorrect processing of the primary 
mitochondrial transcript, a malfunctioning modification or editing of tRNA bases, or an 
incorrect or inhibited loading of the tRNA by the aminoacyl-tRNA-synthetase cannot be 
excIuded. 
Analysis ofthe mitochondrial genes required for functional translation showed that CPEO could 
be caused by a single base substitution. This observation suggests that mtDNA deletions causing 
similar c1inical phenotyps may be based on the same pathogenic mechanism. Hence, it is 
important to consider other yet undiscovered mutations in mitochondrial tRNA or rRNA genes 
as potential contributors to the pathogenesis of CPEO and related neuromuscular disorders. 
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